

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



Rec'd PCT/PTO 20 DEC 2004

(43) International Publication Date
31 December 2003 (31.12.2003)


PCT

(10) International Publication Number
WO 2004/000295 A1

- (51) International Patent Classification⁷: **A61K 31/19**,
A61P 3/06, 3/10, C07C 65/24, 233/78, 235/34, 309/66,
311/13, 323/62, C07D 213/40, 217/06, 277/56, 307/68,
233/60
- (21) International Application Number:
PCT/GB2003/002598
- (22) International Filing Date: 17 June 2003 (17.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0201937-0 20 June 2002 (20.06.2002) SE
- (72) Inventor; and
(75) Inventor/Applicant (for US only): **LI, Lanna** [SE/SE];
AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).
- (74) Agent: **ASTRAZENECA**; Global Intellectual Property,
Mersey, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,
BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE,
DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM,
GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW only): **ASTRAZENECA**
AB [SE/SE]; Sodertälje, S-151 85 (SE).
- (71) Applicant (for MG only): **ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).
- Published:**
— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

[Continued on next page]

(54) Title: BENZOIC ACID DERIVATIVES AS MODULATORS OF PPAR ALPHA AND GAMMA



(57) Abstract: A compound of formula (I) wherein R¹ represents aryl optionally substituted by a heterocyclic group or a hetero-
cyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group -(CH₂)_m-T-
(CH₂)_n-U-(CH₂)_p- is attached at either the 3 or 4 position in the phenyl ring as indicated by the numbers in formula (I) and represents a
group selected from one or more of the following: O(CH₂)₂, O(CH₂)₃, NC(O)NR⁴(CH₂)₂, CH₂S(O₂)NR⁵(CH₂)₂, CH₂N(R⁶)C(O)CH₂,
(CH₂)₂N(R⁶)C(O)(CH₂)₂, C(O)NR⁷CH₂, C(O)NR⁷(CH₂)₂, and CH₂N(R⁶)C(O)CH₂O; V represents O, S, NR⁸, or a single bond; q
represents 1, 2 or 3; W represents O, S, N(R⁹)C(O), NR¹⁰, or a single bond; R² represents halo, a C₁₋₄ alkyl group which is optionally
substituted by one or more fluoro, a C₁₋₄ alkoxy group which is optionally substituted by one or more fluoro, a C₁₋₄ acyl group,
aryl, an aryl C₁₋₄ alkyl group, CN or NO₂; r represents 0, 1, 2 or 3; R³ represents halo, a C₁₋₄ alkyl group which is optionally
substituted by one or more fluoro, a C₁₋₄ alkoxy group which is optionally substituted by one or more fluoro, a C₁₋₄ acyl group,
aryl, an aryl C₁₋₄ alkyl group, or CN; s represents 0, 1, 2 or 3; and R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and R¹⁰ independently represent H,
a C₁₋₁₀ alkyl group, aryl or an aryl C₁₋₄ alkyl group or when m is 0 and T represents a group N(R⁶)C(O) or a group (R⁵)NS(O₂)
then R¹ and R⁶ or R¹ and R⁵ together with the nitrogen atom to which they are attached represent a heteroaryl group; with provisos
and pharmaceutically acceptable salts thereof, processes for preparing such compounds, their utility in treating clinical conditions
associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.